Payment overview · 2025
General Payments
$63.98
3 reported records · 3 companies
Healthcare provider profile · identity verified
Robert Presley Williams, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · WINTER HAVEN, FL · NPI 1538610001
Verified facts
What the public records show
CMS Open Payments records show Robert Presley Williams, ARNP received $63.98 in general payments during 2025 across 3 reported records.
SHIELD THERAPEUTICS INC accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.88 | 38.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.20 | 31.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.90 | 29.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $63.98 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 917 | 307 |
| Amlodipine Besylate | Amlodipine Besylate | 598 | 197 |
| Losartan Potassium | Losartan Potassium | 575 | 187 |
| Lisinopril | Lisinopril | 569 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 538 | 147 |
| Gabapentin | Gabapentin | 436 | 130 |
| Hydrochlorothiazide | Hydrochlorothiazide | 375 | 124 |
| Omeprazole | Omeprazole | 373 | 125 |
| Metformin Hcl | Metformin Hcl | 344 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 297 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 82 |
| Furosemide | Furosemide | 267 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 255 | 92 |
| Tramadol Hcl | Tramadol Hcl | 253 | 79 |
| Glimepiride | Glimepiride | 236 | 78 |
| Trazodone Hcl | Trazodone Hcl | 236 | 77 |
| Montelukast Sodium | Montelukast Sodium | 229 | 70 |
| Alprazolam | Alprazolam | 212 | 39 |
| Methylprednisolone | Methylprednisolone | 207 | 174 |
| Pravastatin Sodium | Pravastatin Sodium | 207 | 65 |
| Simvastatin | Simvastatin | 207 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 64 |
| Famotidine | Famotidine | 192 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 189 | 71 |
| Azithromycin | Azithromycin | 187 | 141 |
| Eliquis | Apixaban | 178 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 49 |
| Pioglitazone Hcl | Pioglitazone Hcl | 163 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 52 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 135 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 50 |
| Clonidine Hcl | Clonidine Hcl | 128 | 50 |
| Potassium Chloride | Potassium Chloride | 126 | 38 |
| Meloxicam | Meloxicam | 124 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 116 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 111 | 67 |
| Carvedilol | Carvedilol | 104 | 34 |
| Prednisone | Prednisone | 101 | 52 |
| Sildenafil Citrate | Sildenafil Citrate | 98 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 35 |
| Lorazepam | Lorazepam | 90 | 23 |
| Baclofen | Baclofen | 85 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 28 |
| Sertraline Hcl | Sertraline Hcl | 84 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 29 |
| Fenofibrate | Fenofibrate | 79 | 25 |
| Donepezil Hcl | Donepezil Hcl | 76 | 32 |
| Lovastatin | Lovastatin | 75 | 22 |
| Xarelto | Rivaroxaban | 74 | 19 |
| Cephalexin | Cephalexin | 73 | 58 |
| Ibuprofen | Ibuprofen | 73 | 23 |
| Finasteride | Finasteride | 71 | 27 |
| Mupirocin | Mupirocin | 69 | 48 |
| Warfarin Sodium | Warfarin Sodium | 69 | 14 |
| Glipizide | Glipizide | 66 | 25 |
| Allopurinol | Allopurinol | 64 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 13 |
| Buspirone Hcl | Buspirone Hcl | 62 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 13 |
| Jardiance | Empagliflozin | 59 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 58 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 56 | 13 |
| Atenolol | Atenolol | 54 | 18 |
| Pregabalin | Pregabalin | 54 | 15 |
| Alendronate Sodium | Alendronate Sodium | 53 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 17 |
| Naproxen | Naproxen | 53 | 20 |
| Nystatin | Nystatin | 53 | 21 |
| Azelastine Hcl | Azelastine Hcl | 52 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 16 |
| Ondansetron Odt | Ondansetron | 49 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 11 |
| Metformin Hcl Er | Metformin Hcl | 48 | 16 |
| Temazepam | Temazepam | 47 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | 22 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Sucralfate | Sucralfate | 43 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 14 |
| Ketoconazole | Ketoconazole | 41 | 23 |
| Memantine Hcl | Memantine Hcl | 41 | 16 |
| Ezetimibe | Ezetimibe | 40 | 13 |
| Fluconazole | Fluconazole | 40 | 20 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 40 | 16 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 18 |
| Terazosin Hcl | Terazosin Hcl | 38 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 24 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 37 | 14 |
| Amoxicillin | Amoxicillin | 36 | 28 |
| Ozempic | Semaglutide | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 21 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 33 | suppressed |
| Ofloxacin | Ofloxacin | 32 | 27 |
| Spironolactone | Spironolactone | 32 | 13 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Epinephrine | Epinephrine | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 13 |
| Mirtazapine | Mirtazapine | 18 | 11 |
| Novolin R | Insulin Regular, Human | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $63.98 · 3 records | SHIELD THERAPEUTICS INC | ACCRUFER, MOUNJARO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error